Sometimes doing nothing is what's best.
The technical signals indicate the odds of further weakness in the health care company's shares are low.
The charts and indicators of ZBRA are touch and go right now.
PFE reported Q1 earnings Tuesday and handily beat expectations.
Both stocks have been underperformers.
The stock of the health plan provider has not been able to show any sustained strength.
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Here are our price objectives.
Let's take a look at 2 charts.
We're now expecting further strength.